
Regeneron has slammed the brakes on its Phase 1 trial of garetosmab in the treatment of the ultra-rare condition fibrodysplasia …
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer

